Maurizio Scaltriti: The importance of bridging the gap between preclinical findings and clinical application
Maurizio Scaltriti, Vice President of Translational Medicine at AstraZenica, shared a post on LinkedIn:
“Read my viewpoint, published in Nature Cancer on the importance of reverse translation medicine, where we interrogate patient samples to study validating measures like mechanisms of action, mechanisms of therapy resistance and disease progression.
While this reverse translation approach requires a culture shift for translational scientists, clinical information together with appropriate preclinical testing and validation systems is essential for drug development and optimizing treatment regimens.
At AstraZeneca we recognize the importance of bridging the gap between preclinical findings and clinical application and are always looking for ways to adapt to the increased sophistication of our drug portfolio and become more creative in harnessing data from the clinic to support discovery research as well as using data from the laboratory for validation.
This is part of our goal of transforming cancer outcomes by combatting metastatic and resistant disease and treating early, with the aim of transforming diagnosis and treatment by focusing on the properties of tumors, and not just their type.”
Breaking frontiers with multidisciplinary cancer research | Nature Cancer
Authors: Carlos Caldas, Xiaoyuan Chen, Li Ding, Jakob Nikolas Kather and Maurizio Scaltriti
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023